Business Wire05.04.16
Dick Aderman, president and CEO of HYCOR Biomedical whose career in the business side of diagnostics and healthcare spans almost four decades, has joined the ImmunArray board of directors.
“We are thrilled to have Dick join the ImmunArray board,” said Donna Edmonds, the company’s CEO and board chairman. “At this time when we are expanding our investor base and our commercial launch, his experience and leadership in the diagnostics industry will make him an invaluable addition to the board. His acumen within the field will help us position ImmunArray and our growing suite of pioneering diagnostic products in a way that accelerates our success. Dick and I were former colleagues, and I welcome the chance to work with him again in helping set the path for ImmunArray’s future as we enter the next phase of company growth.”
Aderman has been president and CEO of HYCOR Biomedical since 2010, helping the Garden Grove, Calif.-based clinical diagnostics company broaden its product line from in-vitro testing into the allergy and autoimmune arena. He formerly served as president of Given Imaging as well as president and chief operating officer of Quadraspec. He spent eight years as a member of the senior management team at Roche Diagnostics, and prior to that, he held various positions in sales, marketing and management with American Hospital Corporation, Baxter Healthcare and Dade International. Aderman also was involved with early and mid-stage start-up companies, developing disease-management software and medical devices.
Aderman served as board chairman of the Indianapolis, Ind., chapter of the American Heart Association. He holds B.B.A. and B.A. degrees from Western Michigan University in Kalamazoo.
“I am very pleased to join the board of this emerging company in the fields of diagnosis and monitoring of the autoimmune and neurologic spaces,” Aderman said. “The response from both the rheumatologists and payers around their SLE-Key product launch has been very impressive, and I look forward to working with Donna and her team again.”
Co-located in Rehovot, Israel and Richmond, Va., ImmunArray is a privately funded molecular diagnostics company developing blood-based tests that support the diagnosis and management of complex acute and chronic immune and neurodegenerative diseases. The company designs and analyzes sets of biomarkers known to be linked to a particular condition and develops tests on platforms that are most appropriate to facilitate the adoption of additional tests. The company, which introduced its first commercial tests, is currently conducting research in collaboration with leading clinicians and medical centers in the United States and Israel. The company was a grant recipient of the GE-NFL Head Health Challenge as well as secured additional corporate research funding to conduct research into the use of biomarkers to identify traumatic brain injury.
“We are thrilled to have Dick join the ImmunArray board,” said Donna Edmonds, the company’s CEO and board chairman. “At this time when we are expanding our investor base and our commercial launch, his experience and leadership in the diagnostics industry will make him an invaluable addition to the board. His acumen within the field will help us position ImmunArray and our growing suite of pioneering diagnostic products in a way that accelerates our success. Dick and I were former colleagues, and I welcome the chance to work with him again in helping set the path for ImmunArray’s future as we enter the next phase of company growth.”
Aderman has been president and CEO of HYCOR Biomedical since 2010, helping the Garden Grove, Calif.-based clinical diagnostics company broaden its product line from in-vitro testing into the allergy and autoimmune arena. He formerly served as president of Given Imaging as well as president and chief operating officer of Quadraspec. He spent eight years as a member of the senior management team at Roche Diagnostics, and prior to that, he held various positions in sales, marketing and management with American Hospital Corporation, Baxter Healthcare and Dade International. Aderman also was involved with early and mid-stage start-up companies, developing disease-management software and medical devices.
Aderman served as board chairman of the Indianapolis, Ind., chapter of the American Heart Association. He holds B.B.A. and B.A. degrees from Western Michigan University in Kalamazoo.
“I am very pleased to join the board of this emerging company in the fields of diagnosis and monitoring of the autoimmune and neurologic spaces,” Aderman said. “The response from both the rheumatologists and payers around their SLE-Key product launch has been very impressive, and I look forward to working with Donna and her team again.”
Co-located in Rehovot, Israel and Richmond, Va., ImmunArray is a privately funded molecular diagnostics company developing blood-based tests that support the diagnosis and management of complex acute and chronic immune and neurodegenerative diseases. The company designs and analyzes sets of biomarkers known to be linked to a particular condition and develops tests on platforms that are most appropriate to facilitate the adoption of additional tests. The company, which introduced its first commercial tests, is currently conducting research in collaboration with leading clinicians and medical centers in the United States and Israel. The company was a grant recipient of the GE-NFL Head Health Challenge as well as secured additional corporate research funding to conduct research into the use of biomarkers to identify traumatic brain injury.